Correct, $STLT is still fighting low volume, small
Post# of 25
If they do the news / advertising on the new first ever product right, they could sell enough of it to close the cash bleed typical of early stage biotechs like $STLT.
For an early real-biotech to already have revenue and a retail product is novel. The stock price should retest the $2 level if the 10-Q in about 4-6 weeks knocks it out of the park. and if they PR it. Also a heavy following of retail customers could bring in retail investors.
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)